Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | USP2 | O75604 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 1/20 | 0.95 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466183 | 0.98 | CYP1A2 (1.00) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Gababutin SCHEMBL2858085 | 0.98 | ALDH1A1 (0.91) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Gabapentin SCHEMBL8343 | 0.98 | CYP1A2 (1.00) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Gabapentin SCHEMBL4030100 | 0.98 | CYP1A2 (1.00) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Gabapentin SCHEMBL179836 | 0.98 | CYP1A2 (1.00) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL6544499 | 0.98 | CYP1A2 (1.00) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Gabapentin SCHEMBL26730 | 0.96 | CYP1A2 (0.96) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Gabapentin SCHEMBL6689206 | 0.96 | CYP1A2 (0.96) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Gabapentin SCHEMBL19031792 | 0.96 | CYP1A2 (0.96) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Gabapentin SCHEMBL6672099 | 0.96 | CYP1A2 (0.96) | ALDH1A1CYP1A2USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423169-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2008-09-09 | — | — | US | claimed |
| WO-2007120485-A2 | METHODS OF TREATING PAIN WITH ALKYLXANTHINES AND ANTIEPILEPTICS AND COMPOSITIONS FOR USE THEREFOR | CINERGEN, LLC (US) | 2007-10-25 | — | — | WO | claimed |
| US-7232924-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2007-06-19 | — | — | US | claimed |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2006-12-21 | — | — | US | claimed |
| EP-1157000-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER LAMBERT CO (US) | 2005-11-02 | — | — | EP | claimed |
| CN-1675165-A | Method for synthesizing acyloxyalkyl derivatives of GABA analogs | XENOPORT INC (US) | 2005-09-28 | — | — | CN | claimed |
| US-20040014940-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2004-01-22 | — | — | US | claimed |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2003-09-18 | — | — | US | claimed |
| EP-1157000-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2001042191-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-06-14 | — | — | WO | claimed |
| EP-0552240-B1 | NEW METHOD OF TREATING DEPRESSION | WARNER LAMBERT CO (US) | 1998-03-18 | — | — | EP | claimed |
| EP-0446570-B1 | Gabapentin and its derivatives for treating neurodegenerative diseases | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | claimed |
| EP-0458751-A1 | Delivery system for cyclic amino acids with improved taste, texture and compressibility | WARNER-LAMBERT COMPANY (US) | 1991-11-27 | — | — | EP | claimed |
| US-4087544-A | Treatment of cranial dysfunctions using novel cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| US-4024175-A | Cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1977-05-17 | — | — | US | claimed |
| WO-2024137742-A1 | COMPOUNDS AND COMPOSITIONS AS FGFR3 DEGRADERS AND USES THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-114929681-B | Bicyclic CX3CR1 receptor agonists | 德州大学系统董事会 | 2024-05-14 | — | — | CN | disclosed |
| US-5025035-A | Administering antidepressants | WARNER-LAMBERT COMPANY (US) | 1991-06-18 | — | — | US | disclosed |
| US-4087544-A | Treatment of cranial dysfunctions using novel cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4024175-A | Cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014940-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | ALDH1A1 495/4885CYP1A2 1323/4885USP2 1225/4885 |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | ALDH1A1 495/4885CYP1A2 1323/4885USP2 1225/4885 |
| US-20030176398-A1 | Prodrugs of GABA analogs, compositions and uses thereof | GABRB1, GABRB2, GABRB3 | ALDH1A1 298/4885CYP1A2 135/4885USP2 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.